Podcasts about jama ophthalmology

Welcome to Ozempic Weightloss Unlocked, the podcast where we break down the latest developments in semaglutide medications and what they mean for your health. I'm your host, and today we're diving into the most important updates from 2025.Let's start with what's working. Ozempic continues to demonstrate significant effectiveness for weight loss, producing mean weight reduction of fourteen point nine to seventeen point four percent over sixty eight weeks in people without diabetes. The higher dose formulation, known as Wegovy, shows even more impressive results, with studies consistently showing greater average weight loss compared to the lower doses found in Ozempic. For millions managing type two diabetes or seeking weight management solutions, these medications have become game changers.But here's what listeners need to know right now. Recent research is raising important safety concerns that demand our attention. A June 2025 study published in JAMA Ophthalmology found that patients taking semaglutide were twice as likely to develop neovascular age related macular degeneration, a condition that gradually destroys central vision. While the absolute risk remains small, researchers from the University of Toronto identified this link as statistically significant. The mechanism makes sense too. Semaglutide alters vascular and inflammatory pathways directly implicated in macular degeneration.The vision concerns aren't the only ones. A January 2025 study in JAMA Otolaryngology found that patients initiating Glucagon like Peptide One receptor agonist therapy had a significantly increased risk of thyroid cancer diagnosis within the first year of use compared to other diabetes medications. Researchers analyzed data from over three hundred fifty thousand adults with type two diabetes.Then there's gastroparesis, the stomach paralysis condition that's become central to ongoing litigation. Multiple lawsuits allege that Novo Nordisk, the manufacturer, failed to provide adequate warnings about this risk. The lawsuits argue the company knew or should have known about the potential link based on clinical studies and medical literature. Patients reported persistent vomiting, nausea, and extreme stomach discomfort after starting the medication.The legal landscape shifted in December 2024 when the Judicial Panel on Multidistrict Litigation ruled to expand the Glucagon like Peptide One receptor agonist lawsuit to include claims involving Saxenda, though blood clot related injuries were excluded due to complexity concerns.What does this mean for you? If you're considering Ozempic or Wegovy, talk to your doctor about these emerging risks alongside the proven benefits. If you're already taking these medications and experiencing vision changes, thyroid issues, or stomach problems, document everything and consult your healthcare provider.The story of Ozempic isn't finished. As evidence emerges, companies face questions not just about what they disclosed but about what they should have investigated. The scientific community continues watching as more data arrives.Thank you so much for tuning in to Ozempic Weightloss Unlocked. Please subscribe to stay updated on the latest developments in semaglutide research and safety updates. This has been a Quiet Please production. For more, check out Quiet Please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Interview with Noemi Lois, MD, PhD, author of Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy. Hosted by Neil Bressler, MD. Related Content: Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy

Interview with Jonathan H. Lass, MD, author of Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate: A Randomized Clinical Trial and of Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study: A Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate Impact of the Diabetes Endothelial Keratoplasty Study

Interview with Nicholas G. Murray, PhD, author of Smooth Pursuit Velocity After a Season of Repetitive Head Impacts in American Football Players. Hosted by Neil Bressler, MD. Related Content: Smooth Pursuit Velocity After a Season of Repetitive Head Impacts in American Football Players

Welcome back to Ozempic Weightloss Unlocked, the podcast dedicated to bringing you the latest news, updates, and insights on Ozempic and its impact on weight, health, and lifestyle.Today, we start with the basics: Ozempic is a medication based on semaglutide, and it is part of a class of drugs called GLP-1 receptor agonists. These drugs work by mimicking a hormone in your gut that helps regulate blood sugar and appetite. According to Purdue University, after a meal, the body naturally releases GLP-1, which helps stimulate insulin production and signals the brain to feel full. Ozempic uses a modified version of this hormone, which not only lowers blood sugar but also reduces appetite, leading to significant weight loss. Clinical studies suggest people can lose between five and twelve percent of their body weight, while also seeing improvements in blood sugar and cardiovascular health.Ozempic is recommended as the first injectable therapy for diabetes by the American Diabetes Association, but most of its headline-grabbing popularity now comes from its off-label use for weight loss. Over fifteen million adults in the United States now use medications like Ozempic, Wegovy, or similar GLP-1-based drugs. The Wall Street Journal reports that this number has been climbing steadily each year.But as more people turn to Ozempic, new challenges and concerns are emerging. The most common side effects are nausea and digestive issues, which can be so severe that up to forty percent of people stop using the drug within the first month, according to Tufts University researchers. Even for those who tolerate Ozempic, there are drawbacks. Experts at Purdue University caution that weight often returns when the drug is discontinued, meaning it is not a permanent fix. Other concerns are rising as well. Mass General Brigham recently published research in JAMA Ophthalmology that links semaglutide to a greater risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause sudden, permanent blindness. People with diabetes taking semaglutide were over four times more likely to develop this disorder than those who did not.At the same time, there is a lot of online buzz around microdosing, or taking very small amounts of GLP-1 drugs for longevity or anti-aging. The Washington Post and The Independent have both reported that leading experts see no solid scientific evidence that microdosing these drugs provides any benefit or is even safe. Companies marketing microdosing protocols are ahead of the actual science.Researchers at Tufts are now developing new medications that target even more hormone receptors, hoping to be more effective, easier to take, and come with fewer side effects. Their most recent breakthrough aims for a four-in-one drug that tackles multiple hormones tied to metabolism and appetite, with the goal of delivering even greater and longer-lasting weight loss. The hope is that future drugs could treat obesity and simultaneously reduce risks for over one hundred eighty diseases linked to excess weight, including diabetes, cancer, and heart disease.Meanwhile, there are also efforts to stimulate the body's own GLP-1 production naturally, possibly through dietary fibers or future supplements. Purdue researchers believe this could help people maintain weight loss after coming off Ozempic, without the harsh side effects of injections, though results so far show milder weight control than with the actual drug.To sum up, Ozempic has opened a new chapter in metabolic medicine, but there are still risks, unanswered questions, and an ever-changing landscape as science races forward. We will be here to keep you informed with the latest evidence and expert insights.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please subscribe so you do not miss our future updates and expert interviews. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

A new JAMA study found that 84% of abortion prescriptions from Aid Access went to patients in states with bans, enabled by “shield laws” protecting telehealth providers across state lines. Provision rates were highest in underserved Southern and Midwestern counties, highlighting telemedicine's role in maintaining access. A Scientific Reports study showed that large language models for clinical use can be manipulated into giving unsafe answers through subtle “adversarial hallucination attacks,” with success rates over 95%. Finally, JAMA Ophthalmology reported GLP-1 agonists may slightly increase risk of sudden vision loss, though benefits still outweigh risks.

Se você atende muitas crianças com exotropia intermitente no consultório, este episódio é para você.Junto com o Dr. Fernando Liebert, vamos discutir o artigo Overminus Lens Therapy for Children 3 to 10 Years of Age With Intermittent Exotropia, publicado no JAMA Ophthalmology.Um bate-papo científico e direto ao ponto, para ajudar na prática clínica e no raciocínio sobre essa abordagem.Não perca! Vamos juntos?Acesse o artigo aqui: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2777181

Interview with Ehsan Rahimy, MD, author of Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy. Hosted by Neil Bressler, MD. Related Content: Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy

Interview with Jennifer R. Rose-Nussbaumer, MD, author of Steroids and Cross-Linking for Ulcer Treatment: The SCUT II Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Steroids and Cross-Linking for Ulcer Treatment

Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

 What conclusions can be drawn from the LIGHTSITE III study examining photobiomodulation for dry AMD? Moderator Barton Blackorby, MD, sits down with panelists Hong-Uyen Hua, MD, and Louis Cai, MD, to examine a recent opinion piece published in JAMA Ophthalmology exploring what researchers can (and cannot) confidently conclude based on the study's data. 

Interview with Susan M. Culican, MD, PhD, author of Gender Differences in Case Volume Among Ophthalmology Resident Graduates, 2014-2023. Hosted by Neil Bressler, MD. Related Content: Gender Differences in Case Volume Among Ophthalmology Resident Graduates, 2014-2023 Training Inequities in Ophthalmology—Insights From Educators

Interview with Arshad M. Khanani, MD, author of Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema

Interview with Harry A. Quigley, MD, author of Shedding LiGHT on Selective Laser Trabeculoplasty, and guest Michael A. Kass, MD, Washington University School of Medicine in St Louis. Hosted by Neil M. Bressler, MD. Related Content: Shedding LiGHT on Selective Laser Trabeculoplasty

Interview with Bradley J. Katz, MD, PhD, author of Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide. Hosted by Neil Bressler, MD. Related Content: Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide

Would you trade temporary weight loss for loss of vision? Recently a study published in JAMA Ophthalmology from Harvard Medical School found evidence that the active ingredient in Semaglutide' in the trendy GLP-1 weight loss drugs such as Wegovy and Ozempic can cause blindness.Dr. Bob Martin answers listeners questions on a variety of topics 

Interview with Benjamin K. Young, MD, MS, author of Ultra-Widefield Optical Coherence Tomography Beyond the Ora Serrata in Retinopathy of Prematurity. Hosted by Neil M. Bressler, MD. Related Content: Ultra-Widefield Optical Coherence Tomography Beyond the Ora Serrata in Retinopathy of Prematurity

Interview with Angeline M. Nguyen, MD, author of Discrimination Within the US Ophthalmology Workforce. Hosted by Neil M. Bressler, MD. Related Content: Discrimination Within the US Ophthalmology Workforce

Interview with Ehsan Rahimy, MD, author of Curcuma-Based Nutritional Supplements and Risk of Age-Related Macular Degeneration. Hosted by Neil M. Bressler, MD. Related Content: Curcuma-Based Nutritional Supplements and Risk of Age-Related Macular Degeneration

Dr. Peter Quiros joins host Dr. Amanda Redfern to discuss the recent JAMA Ophthalmology article "The Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," the first study to report a possible association between semaglutide (Wegovy, Ozempic, Novo Nordisk) and nonarteritic anterior ischemic optic neuropathy (NAION). Dr. Quiros provides an overview of what the study showed and what remains unknown, and how ophthalmologists should discuss these recent findings with their patients. Check out the Semaglutide and NAION patient brochure, courtesy of the North American Neuro-Ophthalmology Society (NANOS), and available from www.nanosweb.org. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Interview with Byron L. Lam, MD, author of Detection and Referral of Depression in Patients With Visual Impairment: A Call for Practical Training and Methods. Hosted by Neil M. Bressler, MD. In the US, you can call, text, or chat 988, the Suicide and Crisis Lifeline. Related Content: Detection and Referral of Depression in Patients With Visual Impairment

Interview with Gerami D. Seitzman, MD, author of Biomarker Detection and Validation for Corneal Involvement in Patients With Acute Infectious Conjunctivitis. Hosted by Neil Bressler, MD. Related Content: Biomarker Detection and Validation for Corneal Involvement in Patients With Acute Infectious Conjunctivitis

Interview with Joseph F. Rizzo III, MD, author of Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Hosted by Neil M. Bressler, MD. Related Content: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

Interview with Cindy X. Cai, MD, MS, author of Neighborhood-Level Social Determinants of Health and Presenting Characteristics for Rhegmatogenous Retinal Detachments. Hosted by Neil Bressler, MD. Related Content: Neighborhood-Level Social Determinants of Health and Presenting Characteristics for Rhegmatogenous Retinal Detachments

Interview with Scott M. Smith, PhD, and Andrew G. Lee, MD, authors of Severe Spaceflight-Associated Neuro-Ocular Syndrome in an Astronaut With 2 Predisposing Factors. Hosted by Neil M. Bressler, MD. Related Content: Severe Spaceflight-Associated Neuro-Ocular Syndrome in an Astronaut With 2 Predisposing Factors

In a recent study published in JAMA Ophthalmology, researchers explored a possible link between the medication semaglutide and a rare type of eye stroke called non-arteritic anterior ischemic optic neuropathy (NAION). In this podcast, we'll explain what this means and why it's important. What is NAION? NAION is a condition that affects the optic nerve, leading to sudden vision loss in one eye. It's considered a rare eye stroke and is not related to artery disease. What is Semaglutide? Semaglutide is a medication used to help manage blood sugar levels in people with type 2 diabetes and is also prescribed for weight loss. It works by increasing insulin secretion in response to meals, which helps regulate blood sugar levels. Semaglutide also helps reduce appetite and increase feelings of satiety, leading to lower calorie intake. It slows the emptying of the stomach, prolonging the feeling of fullness after eating. The Study's Findings The researchers discovered a link between semaglutide and NAION. However, it's important to note that this is just a link. It doesn't prove that semaglutide causes NAION. Showing a connection is only the first step, and proving causation is much more challenging. Possible Explanations Rapid Changes in the Body: When someone starts taking semaglutide, their body undergoes quick cardiovascular and metabolic changes. These changes could trigger NAION, rather than the medication itself being the direct cause. Common Risk Factors: People who take semaglutide often have conditions like high blood pressure, obstructive sleep apnea, or diabetes. These conditions already put them at higher risk for NAION. Semaglutide might just be a common factor among these patients, rather than the cause of their eye issues. Study Limitations The authors note that since their institution specializes in eye conditions, they are more likely to encounter higher numbers of NAION cases. This may limit the generalizability of their findings to other settings. Additionally, the study's records indicate only whether a medication was dispensed to a patient, not whether it was actually taken as prescribed. This distinction is important for accurately assessing the medication's impact.  Furthermore, due to NAION's rarity, the analysis included only a small number of cases, which can complicate the interpretation of statistical results. What Does This All Mean? Scientists need to conduct further studies to determine if semaglutide directly causes NAION or if other factors are at play. And they should be conducted in a larger and more diverse population. Expert Picks: If you'd like to listen about the benefits of semaglutide, check out the following podcasts: Long-Term Health Benefits of Semaglutide for Weight Loss  How GLP-1 Agonists Like Semaglutide Fight Inflammation The Use of GLP-1 Agonists in Post-Heart Attack Care Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The Eversense CGM could soon be approved for one year of continuous use, the first generic GLP-1 medication is launched, a new company tauts and all-in-one sensor and pump infusion set, a new diabetes accessory in the Roblox game, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX The first ever generic GLP-1 medication will soon be available in the US. It's a generic of Victoza, originally approved by the FDA in 2010 for diabetes, is part of the same class of drugs that includes Ozempic and Mounjaro. Liraglutide is Glucagon-like peptide-1 receptor agonists (otherwise known as GLP-1s or GLP-1 RAs) are a class of incretin drugs that mimic the body's natural hormones to help treat diabetes and obesity. However, the popularity of the drugs has spiraled out of control at times, leading to shortages and supply chain issues in the US and abroad.  The arrival of a GLP-1 generic drug provides reasons to be hopeful for doctors and patients alike, but there are also caveats. Couple of caveats - liraglutide is injected once daily (vs. weekly) and many doctors say it doesn't work as well for as many people as semaglutide and terzepatide. No confirmation on the price Two other generic options are being developed and could launch in December 2024. Patents for newer GLP-1 medications like Ozempic and Wegovy won't expire until several years down the road https://www.healthline.com/health-news/victoza-generic-glp1-drug-available XX Senseonics plans to launch a 365-day sensor in the U.S. in the fourth quarter of this year. A one-year Eversense CGM could be a game changer for the company.   In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current 180-day version of Senseonics' implantable Eversense CGM. Eversense's 180-day sensor can need calibrating twice a day, something Senseonics CEO Tim Goodnow said “has been a competitive disadvantage.” Users calibrate the 365-day sensor once a week. Senseonics is in talks with insulin pump manufacturers about integrating its Eversense CGM with their devices but has yet to commit to a timeline for finalizing an agreement. https://www.medtechdive.com/news/senseonics-365-day-cgm-2025-sales/719717/ XX People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn't deter patients from using the medicines to treat diabetes or obesity.   Last summer, doctors at Mass Eye and Ear noticed an unusually high number of patients with non-arteritic anterior ischemic optic neuropathy, or NAION, a type of eye stroke that causes sudden, painless vision loss in one eye.   The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide.   The study, published Wednesday in the medical journal JAMA Ophthalmology, cannot prove that semaglutide medications cause NAION. And the small number of patients — an average of about 100 cases were identified each year — from one specialized medical center may not apply to a broader population. The ways that semaglutides interact with the eyes are not entirely understood. And the exact cause of NAION is not known either. The condition causes damage to the optic nerve, but there is often no warning before vision loss.   For now, patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss, experts say https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-ozempic-linked-with-sight-threatening-eye-disorder-study-2024-07-03/ XX We got some updates at ADA about the over the counter CGMS Dexcom Stelo and Abbot's Libre. Dexom plans a late august launch of stelo, which you'll order from their website – it won't be physically in stores. Abbott also plans to sell its wellness-oriented Lingo device this summer through an e-commerce website. That's a sensor that's been available in other coutnires for a while, but was recently okayed in the US. It's not meant for people with diabetes. The Libre Rio is designed or adulst with type 2 who don't use insulin. No timing yet on that product's launch. Neither Abbott nor Dexcom have disclosed pricing for the upcoming products. https://www.medtechdive.com/news/abbott-dexcom-over-the-counter-cgm-launch/719928/ XX Insulet is looking to expand the label for its Omnipod 5 insulin pump for people with Type 2 diabetes. The company said Friday it recently filed with the Food and Drug Administration. Insulet presented study results at the American Diabetes Association's 84th Scientific Sessions that evaluated Omnipod 5 in people with Type 2 diabetes who were taking basal insulin or multiple daily injections. The results showed “substantial improvements in blood glucose outcomes and overall quality of life,” said study chair Francisco Pasquel, an associate professor of endocrinology at Emory School of Medicine. Omnipod 5 is currently cleared in the U.S. for people with Type 1 diabetes. Insulet hopes to expand the pump to people with Type 2 diabetes, with an expected launch in early 2025. The FDA has not yet cleared any automated insulin delivery systems for people with Type 2 diabetes, Insulet said. The company has a basal-only insulin pump, called Omnipod Go, that was cleared for people with Type 2 diabetes last year, but it does not connect to other devices. Even though Omnipod 5 is not currently indicated for Type 2 diabetes, doctors prescribe it for their patients with full reimbursement since the pharmacy channel doesn't distinguish between Type 1 or Type 2 patients, J.P. Morgan analyst Robbie Marcus wrote in a research note on Sunday. https://www.medtechdive.com/news/insulet-omnipod-5-type-2-diabetes-study/719644/ XX In the keynote address at the American Diabetes Association annual conference, FDA Commissioner Dr. Robert Califf expressed concerns about the rising rates of diabetes in the U.S. Though revolutionary medications and technologies for diabetes and weight loss continue to emerge, these treatments are vastly underused. The silver lining lies with type 1 diabetes therapies, which are showing great promise in clinical trials. “For the larger epidemic of type 2 diabetes, we're failing right now,” Califf said. “I don't say that lightly.” A huge problem, Califf said, is access. While most health insurance plans cover medical devices and medications for diabetes, without insurance, costs add up quickly. Ozempic, for example, costs nearly $1,000 per month without insurance. Studies have found that regardless of insurance status, roughly 26% of Americans skipped or delayed treatment due to cost. https://diatribe.org/diabetes-management/fda-commissioner-says-were-failing-people-type-2-diabetes XX Embecta presented two abstracts at the American Diabetes Association Scientific Sessions last weekend making the case for its insulin patch pump for Type 2 diabetes. The company submitted the device for Food and Drug Administration clearance in late 2023. The diabetes device company developed a patch pump with a larger insulin reservoir that can hold up to 300 units. Embecta, which is better known for making equipment such as pen needles and insulin syringes, has been developing its first patch pump. The company found that a device with a larger insulin reservoir could provide longer wear times and fewer disposable patches. https://www.medtechdive.com/news/embecta-insulin-patch-pump-volume-american-diabetes-association/719779/ XX   Pump/CGM sensor in one The niaa signature patch pump, shown with a watch displaying current blood sugar level The niaa signature patch pump has a manual bolus button and is part of an in-development AID system. Swiss technology maker Pharmasens demonstrated a new semi-reusable tubeless patch pump and glucose sensor in the same compact device, called the niia signature, which the company says can be worn for five days.   The top of the device, which includes Bluetooth connectivity and the electronic and mechanical parts to control the pump, separates from the disposable 300-unit reservoir along with the adhesive used to attach the device to the body via a steel cannula. A small button on the device allows manual bolusing. The company says an AID system will manage the device, controlled by smartphone.   PharmaSens' simpler basal-bolus patch pump, the niia essential, was submitted for FDA approval in late December. Availability of the niia signature AID system has yet to be announced. https://diatribe.org/diabetes-technology/diabetes-technology-display-ada-2024 XX Edgepark Commercial XX New international consensus statement offers guidance on the care and monitoring of people who are at high risk for type 1 diabetes (T1D). This is all about screening and testing for islet autoantibodies. These individuals are classified as: At risk or Stage 0 (single autoantibody or transient single autoantibody), Stage 1 (two or more autoantibodies with normoglycemia), and Stage 2 (two or more autoantibodies with dysglycemia but without symptoms and not yet meeting diagnostic criteria for Stage 3 clinical T1D). The document was presented on June 24, 2024 in a 90-minute symposium at the American Diabetes Association's annual Scientific Sessions and published simultaneously in both Diabetes Care and Diabetologia. "This is not guidance around who to screen or when to screen. This is guidance for the hundreds of thousands of people around the world who have participated in screening, mostly through research programs, and have been identified with positive autoantibodies and need care in the clinical setting," panel co-chair Anastasia Albanese-O'Neill, PhD, APRN, CDCES, of Breakthrough T1D, told Medscape Medical News.   The recommendations also include when to start insulin, and how to provide education and psychosocial support to individuals and family members of those given the early-stage T1D diagnosis. https://www.medscape.com/viewarticle/experts-advise-early-risk-monitoring-type-1-diabetes-2024a1000bpo XX Roblox has added a diabetic option, complete with insuli pen and Dexcom You can find it in the marketplace JDRF – now breakthrough t1d – started a world in roblox a couple of years ago as well Roblox is a super popular online game that a lot of kids play. https://www.roblox.com/games/5823990610/Breakthrough-T1D-World XX FFL next week! Join us again soon!

Interview with Carolyn Drews-Botsch, PhD, author of Patching in Children With Unilateral Congenital Cataract and Child Functioning and Parenting Stress. Hosted by Neil M. Bressler, MD. Related Content: Patching in Children With Unilateral Congenital Cataract and Child Functioning and Parenting Stress

Interview with David B. Rein, PhD, author of Prevalence of Diabetic Retinopathy in Health Care Settings—An Early Warning Sign? Hosted by Neil M. Bressler, MD. Related Content: Prevalence of Diabetic Retinopathy in Health Care Settings—An Early Warning Sign?

The field of retina has made significant strides when it comes to diversity, equity, and inclusion since Julia A. Haller, MD, penned her inspirational 2015 JAMA Ophthalmology editorial, Cherchez la Femme. The ever-growing body of research on this topic stands as a testament to her commitment to understanding the gaps in diversity, particularly in terms of gender differences in leadership positions. Adrienne W. Scott, MD, and Steven Sanislo, MD, sit down with Dr. Haller to discuss the state of affairs in retina and just how far we have come—and how much is left to do.  How are we doing in terms of representation on the podium? How does diversity among retina specialists affect patient care? Why is it important to look for diversity when designing an ad board or conference agenda? What drove Dr. Haller to pursue a career in a traditionally male-dominated field? Check out this episode to hear what Dr. Haller has to say. 

Interview with Paolo S. Silva, MD, and Jennifer K. Sun, MD, MPH, authors Automated Machine Learning for Predicting Diabetic Retinopathy Progression From Ultra-Widefield Retinal Images. Hosted by Neil M. Bressler, MD. Related Content: Automated Machine Learning for Predicting Diabetic Retinopathy Progression From Ultra-Widefield Retinal Images

Interview with Sophia Y. Wang, MD, MS, author of Social Determinants of Health and Perceived Barriers to Care in Diabetic Retinopathy Screening. Hosted by Neil Bressler, MD. Related Content: Social Determinants of Health and Perceived Barriers to Care in Diabetic Retinopathy Screening

Interview with Prithvi Mruthyunjaya, MD, MHS, author of Risk of Stroke, Myocardial Infarction, and Death After Retinal Artery Occlusion. Hosted by Neil M. Bressler, MD. Related Content: Risk of Stroke, Myocardial Infarction, and Death After Retinal Artery Occlusion

Interview with Scott M. McClintic, MD, author of Assessing Strategies to Reduce the Carbon Footprint of the Annual Meeting of the American Academy of Ophthalmology. Hosted by Neil Bressler, MD. Related Content: Assessing Strategies to Reduce the Carbon Footprint of the Annual Meeting of the American Academy of Ophthalmology

Interview with Michael X. Repka, MD, MBA, author of Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control

Interview with Carol Y. Cheung, PhD, author of Assessment of Parafoveal Diabetic Macular Ischemia on Optical Coherence Tomography Angiography Images to Predict Diabetic Retinal Disease Progression and Visual Acuity Deterioration. Hosted by Neil Bressler, MD. Related Content: Assessment of Parafoveal Diabetic Macular Ischemia on Optical Coherence Tomography Angiography Images to Predict Diabetic Retinal Disease Progression and Visual Acuity Deterioration

Interview with Rishi P. Singh, MD, author of Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data. Hosted by Neil Bressler, MD. Related Content: Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data

Interview with Isdin Oke, MD, author of Factors Associated With Nasolacrimal Duct Probing Failure Among Children in the Intelligent Research in Sight Registry. Hosted by Neil Bressler, MD. Related Content: Factors Associated With Nasolacrimal Duct Probing Failure Among Children in the Intelligent Research in Sight Registry

Myopia has escalated to epidemic proportions with a global prevalence twice that of obesity. A study published in JAMA Ophthalmology in 2021 found the prevalence of myopia in six-year-old children in China jumped from 5.7% between 2015 and 2019 to 21.5% in 2020. Given myopia affects about 40% of Americans and up to 90% of the East and Southeast Asians, it's time to pick up the pace on education, treatment, and management. At OIS XII in San Diego, a panel of experts discussed how the eye care community can make a difference in myopia within the pediatric population. Moderated by David Kading, OD, of Specialty Eye in Seattle, Washington, the group discussed current FDA-approved and off-label treatments, as well as emerging solutions. They also discussed the importance of raising parent awareness to reduce risk and progression of this disease. Listen to the podcast today to hear the panelists discuss: ·         What's happening now in the myopia management space.·         Is myopia a disease?·         Exciting myopia developments coming in the next two to three years·         Steps to improve parent and patient education around myopia·         What it will take to significantly accelerate myopia treatment development and commercialization in the next five years·         Promising investment opportunities in myopia over the next five years Speakers:Robert A. Clark, MD—South Bay Family Eye/Associate Clinical Professor of Ophthalmology, Stein Eye InstituteRajeev Garg, PhD—Global Head, Myopia Management Strategy, CooperVisionMatt Oerding—Board Member, GMAC/CEO & Co-Founder, Treehouse EyesDavid Kading, OD, FAAO, FCLSA—CEO, Specialty Eye (moderator) Hit “Play” to Listen.

Interview with Erick D. Bothun, MD, author of Incidence of Glaucoma-Related Adverse Events in the First 5 Years After Pediatric Lensectomy. Hosted by Neil Bressler, MD. Related Content: Incidence of Glaucoma-Related Adverse Events in the First 5 Years After Pediatric Lensectomy

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Interview with Brian L. VanderBeek, MD, MPH, MSCE, author of Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy. Hosted by Neil Bressler, MD. Related Content: Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

Interview with Tianjing Li, MD, MHS, PhD, author of Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis. Hosted by Neil Bressler, MD.

Interview with Divya Srikumaran, MD, author of Association Between Parental Leave and Ophthalmology Resident Physician Performance. Hosted by Neil Bressler, MD.

Interview with Adam R. Glassman, MS, and Jennifer K. Sun, MD, MPH, authors of Association of Predominantly Peripheral Lesions on Ultrawide Field Imaging and the Risk of Diabetic Retinopathy Worsening Over Time. Hosted by Neil Bressler, MD.

Interview with Arun D. Singh, MD, author of Predicted vs Observed Metastasis-Free Survival in Individuals With Uveal Melanoma. Hosted by Neil Bressler, MD.

Interview with Alison G. Abraham, MHS, MS, PhD, author of Association of Optical Coherence Tomography and Optical Coherence Tomography Angiography Retinal Features With Visual Function in Older Adults. Hosted by Neil Bressler, MD.

In July 2022, Kirsten Bibbins-Domingo, PhD, MD, MAS, took on a new role as the 17th editor in chief of JAMA and the JAMA Network. In conversation with Nobel laureate Harold Varmus, MD, Bibbins-Domingo discusses her research background, approaches to leadership in health care, and the critical role that journals play in communication about public health and science. Related Content: The Urgency of Now and the Responsibility to Do More—My Commitment for JAMA and the JAMA Network A Conversation With Dr Kirsten Bibbins-Domingo, JAMA's New Editor in Chief (video) A Conversation With Dr Kirsten Bibbins-Domingo, JAMA's New Editor in Chief (audio)

Interview with Sobha Sivaprasad, author of Multicenter Evaluation of Diagnostic Circulating Biomarkers to Detect Sight-Threatening Diabetic Retinopathy